Abstract
Previous studies reported that the Tumor Susceptibility Gene 101 (TSG101) is upregulated in selected human malignancies, and the expression of exogenous Tsg101 was suggested to transform immortalized fibroblasts in culture. To date, the potential oncogenic properties of Tsg101 have not been examined in vivo owing to the lack of appropriate model systems. In this study, we show that Tsg101 is highly expressed in a subset of invasive human breast cancers. Based on this observation, we generated the first transgenic mouse model with a targeted overexpression of Tsg101 in the developing mammary gland to test whether exogenous Tsg101 is capable of initiating tumorigenesis. Normal functionality of exogenous Tsg101 was tested by rescuing the survival of Tsg101-deficient mammary epithelial cells in conditional knockout mice. The overexpression of Tsg101 resulted in increased phosphorylation of the epidermal growth factor receptor and downstream activation of MAP kinases. Despite an increase in the activation of these signal transducers, the mammary gland of females expressing exogenous Tsg101 developed normally throughout the reproductive cycle. In aging females, the overexpression of Tsg101 seemed to increase the susceptibility of mammary epithelia toward malignant transformation. However, owing to the long latency of tumor formation and the sporadic occurrence of bona fide mammary cancers, we conclude that the Tsg101 protein has only weak oncogenic properties. Instead of cancer initiation, it is therefore likely that Tsg101 plays a more predominant role in the progression of a subset of spontaneously arising breast cancers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Babst M, Odorizzi G, Estepa EJ, Emr SD . (2000). Mammalian tumor susceptibility gene 101 (TSG101) and the yeast homologue, Vps23p, both function in late endosomal trafficking. Traffic 1: 248–258.
Burdon T, Sankaran L, Wall RJ, Spencer M, Hennighausen L . (1991). Expression of a whey acidic protein transgene during mammary development. Evidence for different mechanisms of regulation during pregnancy and lactation. J Biol Chem 266: 6909–6914.
Carstens MJ, Krempler A, Triplett AA, van Lohuizen M, Wagner KU . (2004). Cell cycle arrest and cell death are controlled by p53-dependent and p53-independent mechanisms in Tsg101-deficient cells. J Biol Chem 279: 35984–35994.
Cerrito MG, Galbaugh T, Wang W, Chopp T, Salomon D, Cutler ML . (2004). Dominant negative Ras enhances lactogenic hormone-induced differentiation by blocking activation of the Raf-Mek-Erk signal transduction pathway. J Cell Physiol 201: 244–258.
Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K et al. (1999). Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 13: 2604–2616.
Chin LS, Raynor MC, Wei X, Chen HQ, Li L . (2001). Hrs interacts with sorting nexin 1 and regulates degradation of epidermal growth factor receptor. J Biol Chem 276: 7069–7078.
Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE et al. (2001). Tsg101 and the vacuolar protein sorting pathway are essential for hiv-1 budding. Cell 107: 55–65.
Gayther SA, Barski P, Batley SJ, Li L, de Foy KA, Cohen SN et al. (1997). Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene 15: 2119–2126.
Hennighausen L, Robinson GW . (2001). Signaling pathways in mammary gland development. Dev Cell 1: 467–475.
Hittelman AB, Burakov D, Iniguez-Lluhi JA, Freedman LP, Garabedian MJ . (1999). Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins. EMBO J 18: 5380–5388.
Katzmann DJ, Babst M, Emr SD . (2001). Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell 106: 145–155.
Krempler A, Henry MD, Triplett AA, Wagner KU . (2002). Targeted deletion of the Tsg101 gene results in cell cycle arrest at G1/S and p53-independent cell death. J Biol Chem 277: 43216–43223.
Lee MP, Feinberg AP . (1997). Aberrant splicing but not mutations of TSG101 in human breast cancer. Cancer Res 57: 3131–3134.
Li L, Cohen SN . (1996). Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85: 319–329.
Li L, Li X, Francke U, Cohen SN . (1997). The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell 88: 143–154.
Liu RT, Huang CC, You HL, Chou FF, Hu CC, Chao FP et al. (2002). Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Oncogene 21: 4830–4837.
Lo YF, Chen TC, Chen SC, Chao CC . (2000). Aberrant expression of TSG101 in Taiwan Chinese breast cancer. Breast Cancer Res Treat 60: 259–266.
Mahler JF, Stokes W, Mann PC, Takaoka M, Maronpot RR . (1996). Spontaneous lesions in aging FVB/N mice. Toxicol Pathol 24: 710–716.
Merlo GR, Graus-Porta D, Cella N, Marte BM, Taverna D, Hynes NE . (1996). Growth, differentiation and survival of HC11 mammary epithelial cells: diverse effects of receptor tyrosine kinase-activating peptide growth factors. Eur J Cell Biol 70: 97–105.
Raiborg C, Bache KG, Mehlum A, Stang E, Stenmark H . (2001). Hrs recruits clathrin to early endosomes. EMBO J 20: 5008–5021.
Ruland J, Sirard C, Elia A, MacPherson D, Wakeham A, Li L et al. (2001). p53 Accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101. Proc Natl Acad Sci USA 98: 1859–1864.
Steiner P, Barnes DM, Harris WH, Weinberg RA . (1997). Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer. Nat Genet 16: 332–333.
Sun Z, Pan J, Bubley G, Balk SP . (1997). Frequent abnormalities of TSG101 transcripts in human prostate cancer. Oncogene 15: 3121–3125.
Wagner KU, Dierisseau P, Rucker EB, Robinson GW, Hennighausen L . (1998). Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants. Oncogene 17: 2761–2770.
Wagner KU, Krempler A, Qi Y, Park K, Henry MD, Triplett AA et al. (2003). Tsg101 is essential for cell growth, proliferation, and cell survival of embryonic and adult tissues. Mol Cell Biol 23: 150–162.
Wakefield LM, Thordarson G, Nieto AI, Shyamala G, Galvez JJ, Anver MR et al. (2003). Spontaneous pituitary abnormalities and mammary hyperplasia in FVB/NCr mice: implications for mouse modeling. Comp Med 53: 424–432.
Watanabe M, Yanagi Y, Masuhiro Y, Yano T, Yoshikawa H, Yanagisawa J et al. (1998). A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled-coil domain. Biochem Biophys Res Commun 245: 900–905.
Zhong Q, Chen Y, Jones D, Lee WH . (1998). Perturbation of TSG101 protein affects cell cycle progression. Cancer Res 58: 2699–2702.
Zhu G, Reynolds L, Crnogorac-Jurcevic T, Gillett CE, Dublin EA, Marshall JF et al. (2003). Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer. Oncogene 22: 3742–3748.
Acknowledgements
We are grateful to Dr Robert Cardiff (UC Davis) for providing his expertise in pathology and for the histopathological annotation of images from digitized whole-slide-scanned sections of selected tumor specimen. We thank the members of the UNMC Mouse Genome Engineering Core Facility for performing the pronuclear injections. This work was supported by the Public Health Service grant CA93797 from the National Cancer Institute. Additional financial support provided to KUW by the Nebraska Research Initiative was imperative to finance the maintenance of the mice. MJS received a graduate fellowship through the Nebraska IDeA Networks of Biomedical Research Excellence (Grant No. P20 RR16469).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Oh, K., Stanton, M., West, W. et al. Tsg101 is upregulated in a subset of invasive human breast cancers and its targeted overexpression in transgenic mice reveals weak oncogenic properties for mammary cancer initiation. Oncogene 26, 5950–5959 (2007). https://doi.org/10.1038/sj.onc.1210401
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210401
Keywords
This article is cited by
-
Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment
Journal of Hematology & Oncology (2019)
-
Endocytic control of growth factor signalling: multivesicular bodies as signalling organelles
Nature Reviews Molecular Cell Biology (2012)
-
An upstream regulatory element confers orientation-independent enhancement of the TSG101 promoter activity in transformed cells
Molecular Biology Reports (2012)
-
TSG101, identified by screening a cancer cDNA library and soft agar assay, promotes cell proliferation in human lung cancer
Molecular Biology Reports (2010)
-
Derailed endocytosis: an emerging feature of cancer
Nature Reviews Cancer (2008)